An observational study in Renal Cell Carcinoma, Urothelial Carcinoma and Bladder Cancer, sponsored by Fox Chase Cancer Center. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Fox Chase Cancer Center · Observational
This is a comparative study using resected/ biopsied tumors samples collected from renal cell carcinoma and urothelial carcinoma patients who underwent surgical removal of lesions, followed by immune checkpoint blockade (ICB) treatment targting programmed cell death 1 (PD1) but developed new lesions later were also removed and stored in the biosample repository (BSR). The histology and genomic analysis of the pre-treatment and metastatic samples from the same patient would be used to find out the changes that may have lead to metastasis. Also, metastatic samples from ICB naive patients would be collected and compared with those from ICB treated patients to find out if the metastasis in treated patients was due to development of reistance.
RCC and UC patients who were treated with ICB but developed metastatis post-treatment that was resected
Exclusion Criteria:
-
Patients who were treated with immune checkpoint inhibitor targeting PD1 and developed metastatic lesion later
Biological: Immune checkpoint inhibitor targeting PD1
Patients who were not treated with immune checkpoint inhihibitor and developed metastatic lesion following other targeted therapy
RCC and UC patients treated with immune checkpoint blockade
Histopathological characterization of samples from ICB treated patients
To characterize differences in histopathology and patterns of genomic expression between baseline tumors and metastases exhibiting divergent growth kinetics ("escape" metastases) in patients treated with immune checkpoint blockade (ICB)
Time frame: 18 months
Genomic characterization of samples from ICB treated patients
To characterize expression of different genes between baseline tumors and metastases exhibiting divergent growth kinetics ("escape" metastases) in patients treated with immune checkpoint blockade (ICB)
Time frame: 18 months
Histopathological characterization of samples from patients treated with targeted or observational therapy
To characterize differences in histopathology between baseline tumors and metastases in patients with RCC treated with observation or targeted therapy.
Time frame: 18 months
Comparison of Histopathological characteristics of metastatic samples from ICB naive and treated patients
To characterize differences in histopathology and patterns of genomic expression between "escape" metastases in patients treated with ICB from patients treated with targeted therapy or observation.
Time frame: 18 months
Genomic characterization of samples from patients treated with targeted or observational therapy
To characterize differences in patterns of genomic expression between baseline tumors and metastases in patients with RCC treated with observation or targeted therapy
Time frame: 18 months
Comparison of genomic characteristics of metastatic samples from ICB naive and treated patients
To characterize differences in patterns of genomic expression between "escape" metastases in patients treated with ICB from patients treated with targeted therapy or observation.
Time frame: 18 months
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fox Chase Cancer Center